Alvimopan
Alvimopan (alvimopan) is a small molecule pharmaceutical. Alvimopan was first approved as Entereg on 2008-05-20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Alvimopan (discontinued: Entereg)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alvimopan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ENTEREG | Cubist Pharmaceuticals | N-021775 DISCN | 2008-05-20 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alvimopan | ANDA | 2024-02-08 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Alvimopan, Entereg, Cubist Pharms | |||
| 8946262 | 2030-02-12 | U-1655 | |
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ileus | D045823 | — | K56.7 | — | 1 | 5 | 3 | 3 | 12 |
| Gastrointestinal diseases | D005767 | — | — | — | 2 | 3 | 1 | — | 6 |
| Constipation | D003248 | — | K59.0 | — | 2 | 3 | 1 | — | 6 |
| Acute pain | D059787 | — | R52 | — | — | — | 1 | — | 1 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intestinal diseases | D007410 | — | K63.9 | — | 2 | 7 | — | — | 9 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | 2 | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | 1 | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | — | — | 1 | — | — | 1 |
| Peritoneal neoplasms | D010534 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 2 | — | — | — | 2 |
| Cancer pain | D000072716 | — | G89.3 | — | 1 | — | — | — | 1 |
| Opioid-induced constipation | D000079689 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute abdomen | D000006 | — | R10.0 | — | — | — | — | 1 | 1 |
| Ventral hernia | D006555 | EFO_1001866 | K43 | — | — | — | — | 1 | 1 |
| Hernia | D006547 | — | K40-K46 | — | — | — | — | 1 | 1 |
| Spinal fusion | D013123 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alvimopan |
| INN | alvimopan |
| Description | Alvimopan is a peptide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 156053-89-3 |
| RxCUI | 1516803 |
| ChEMBL ID | CHEMBL270190 |
| ChEBI ID | — |
| PubChem CID | 5488548 |
| DrugBank | DB06274 |
| UNII ID | Q153V49P3Z (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 653 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alvimopan
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
305 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use